Document Detail

Does comorbidity explain trends in prescribing of newer antihypertensive agents?
MedLine Citation:
PMID:  15480107     Owner:  NLM     Status:  MEDLINE    
OBJECTIVE: Concerns exist about heavily prescribing of new drugs when the evidence on hard outcomes is still limited. This has been the case for the newer classes of antihypertensives, especially in hypertensive patients without additional comorbidity. The association between comorbidity and trends in prescribing of angiotensin-converting enzyme inhibitors (ACE-I) and angiotensin II receptor blockers (ARBs) was examined for the period 1996-2000. DESIGN AND METHODS: Data were obtained from the Integrated Primary Care Information database, which contains medical records from more than 100 general practitioners in the Netherlands. Prevalent drug use in hypertensive patients was determined per calendar year. As initial treatment, the first antihypertensive drug prescribed within 1 year after diagnosis of hypertension was considered. Logistic regression was used to estimate the likelihood of receiving either ACE-I or ARBs. RESULTS: The overall prevalent ACE-I use remained stable (31%), but it increased from 33 to 41% in hypertensive patients with diabetes, heart failure, proteinuria and/or renal insufficiency. ARB use increased significantly from 2 to 12%; this trend did not differ between patients with or without specific comorbidities. Initial ACE-I use slightly decreased (from 29% to 24%), whereas initial ARB use significantly increased (from 4% to 12%). ACE-I were more likely to be the first treatment in patients with diabetes [odds ratio (OR)=3.9; 95% confidence interval (CI) 3.2-4.9] or hypercholesterolemia (OR=1.4; 95% CI 1.1-1.8). ARBs were more likely to be the initial treatment in patients with asthma/chronic obstructive pulmonary disease (OR=1.6; 1.2-2.3), diabetes (OR=2.1; 1.5-2.9) or hypercholesterolemia (OR=1.7; 1.2-2.4). CONCLUSIONS: The increased use of ACE-I is mostly restricted to hypertensive patients with comorbidities for which their use has been recommended. Trends in prescribing of ARBs are not related to relevant comorbidities.
Jacoba P Greving; Petra Denig; Willem Jan van der Veen; Frank W Beltman; Miriam C J M Sturkenboom; Dick de Zeeuw; Flora M Haaijer-Ruskamp
Related Documents :
16977747 - Bilateral renal artery stenosis and renovascular hypertension.
21127977 - Correlation of c-reactive protein with clinical and endoscopic activity in patients wit...
15006937 - White coat hypertension in patients with obstructive sleep apnea-hypopnea syndrome.
21274387 - Pernicious anemia: what are the actual diagnosis criteria?
23467027 - Papillary thyroid cancer and inflammatory bowel disease: is there a relationship?
25215117 - Urokinase-type plasminogen activator receptor as a predictor of poor outcome in patient...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of hypertension     Volume:  22     ISSN:  0263-6352     ISO Abbreviation:  J. Hypertens.     Publication Date:  2004 Nov 
Date Detail:
Created Date:  2004-10-13     Completed Date:  2005-02-16     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  8306882     Medline TA:  J Hypertens     Country:  England    
Other Details:
Languages:  eng     Pagination:  2209-15     Citation Subset:  IM    
Department of Clinical Pharmacology, University of Groningen, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Angiotensin II Type 1 Receptor Blockers / therapeutic use
Angiotensin-Converting Enzyme Inhibitors / therapeutic use
Antihypertensive Agents / therapeutic use*
Databases, Factual
Hypertension / drug therapy*,  mortality*
Middle Aged
Physician's Practice Patterns*
Reg. No./Substance:
0/Angiotensin II Type 1 Receptor Blockers; 0/Angiotensin-Converting Enzyme Inhibitors; 0/Antihypertensive Agents

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Nebivolol improves coronary flow reserve in hypertensive patients without coronary heart disease.
Next Document:  Low-renin status in therapy-resistant hypertension: a clue to efficient treatment.